In the same way, Meldi et al. [33] identified 167 differentially methylated regions of DNA at baseline in chronic myelomonocytic leukemia that distinguished responders from nonresponders to decitabine, and Voso et al. [34] described that BCL2L10 methylation at diagnosis may predict response to AZA in MDS patients. This evidence concerns the gene BCL2L10 and myelodysplastic syndrome.